Join me & MIA multidisciplinary experts at Neoadjuvant Treatment Symposium, to help clinicians navigate the evolving treatment landscape for #melanoma, after recent PBS listing for #neoadjuvant regimens. Mon evening 24 Nov AEDT in person in Sydney, or online. events.humanitix.com/neoadjuvant-...

Neoadjuvant treatment in 2025

Advance your expertise in neoadjuvant therapy and melanoma care at our upcoming symposium for multidisciplinary specialists.

events.humanitix.com

INNOVATE Naples - Paolo Ascierto hosts clinician/researchers discussing #CANCER #NEOADJUVANT #immunotherapy. Favorite meeting for patient-centered novel trials. Discussed optimising immunotherapy across multiple cancers & #melanoma to cure more Grazie tutti!

Important week - #UnitedNation international #women’s day week! Honoured to speak about courage, unconscious bias, inspiration, and my 5 best pieces advice 4 action & change. #ING #marieclaire #NSWeducation #RoyalSocietyNSW @sydneyuni.bsky.social @melanomaau.bsky.social

This #science exciting! Collaborate, #clincaltrials, nurses, scientists - my co-lead H Rizos🤩. #immunotherapy 4 #GBM #glioblastoma Handed draft trial design+drugs to @jimwhittle.bsky.social @braincancercentre.bsky.social @sydneyuni.bsky.social @melanomaau.bsky.social www.nature.com/articles/s41...

Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma - Nature Medicine

A patient with newly diagnosed glioblastoma was safely treated with neoadjuvant nivolumab, relatlimab and ipilimumab before maximal resection, with comprehensive immune profiling showing the induction...

nature.com

www.smh.com.au/national/can... @sydneyuni.bsky.social @wehi-research.bsky.social @jimwhittle.bsky.social @braincancercentre.bsky.social @melanomaau.bsky.social @science.org.au @ascocancer.bsky.social @ascopost.bsky.social @sitcancer.bsky.social

Can this melanoma therapy beat brain cancer? We’re about to find out

A world-first clinical trial will investigate whether the experimental treatment given to a former Australian of the Year can treat aggressive tumours in other patients.

smh.com.au

So proud of this aussie trial - changed practice. @melanomaau.bsky.social @sydneyuni.bsky.social @science.org.au Ipilimumab + nivolumab vs nivolumab in patients with #melanoma brain metastases (ABC): 7-yr follow-up of randomised, ph 2 study - The Lancet Oncology www.thelancet.com/journals/lan...

Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study

Our findings suggest that ipilimumab plus nivolumab maintains efficacy to at least 7 years in patients with active asymptomatic brain metastasis. Upfront ipilimumab plus nivolumab should be the standa...

thelancet.com

Welcome ‘25 @melanomaau.bsky.social fellows. Ciao fab Drs fr 2024 Ruby, Bec & Andea, work with top #clinicaltrials team & advance practice #nurses. Togeth we deliver #cancer care, keep patients SAFE & push boundaries - 0 deaths fr #melanoma. ❤️ Working to make a difference-Highlight of my work week.

Celebrating #australianoftheyear 2025 with my kids (1 in USA), my rock of a husband&my wise Mum. Lost Dad in 2024 ❤️ but made pioneering #melanoma research & transformed clinical practice, groundbreaking science with brilliant women, exploring Australia & #changemakers. youtu.be/VfJKuE114Do?...

What an amazing group of 2025 Australians of the Year! Tears flowed freely as their stories were told - Neale #fightnmd, Olly #wheelchairs for kids, Katrina #QUT and Vanessa & Hannah #cafesteppingstone. Making #Australia a better place! @sydneyuni.bsky.social @melanomaau.bsky.social #AOTY

Looking fwd to 2025 - #clinicaltrials to cure #cancer & #melanoma, & #immunotherapy. My 2024 highlights: www.nejm.org/doi/abs/10.1... www.nejm.org/doi/full/10.... www.annalsofoncology.org/article/S092... ascopubs.org/doi/10.1200/... ascopubs.org/doi/10.1200/... www.nature.com/articles/s41...

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma | NEJM

In phase 1–2 trials in patients with resectable, macroscopic stage III melanoma, neoadjuvant immunotherapy was more efficacious than adjuvant immunotherapy. In this phase 3 trial, we randomly assig...

nejm.org